Abstract
Image-guided ablation (IGA) techniques have evolved considerably over the past 20 years and are increasingly used to definitively treat small primary cancers of the liver and kidney. IGA is recommended by most guidelines as the best therapeutic choice for patients with early stage hepatocellular carcinoma (HCC)-defined as either a single tumour smaller than 5 cm or up to three nodules smaller than 3 cm-when surgical options are precluded, and has potential as first-line therapy, in lieu of surgery, for patients with very early stage tumours smaller than 2 cm. With regard to renal cell carcinoma, despite the absence of any randomized trial comparing the outcomes of IGA with those of standard partial nephrectomy, a growing amount of data demonstrate robust oncological outcomes for this minimally invasive approach and testify to its potential as a standard-of-care treatment. Herein, we review the various ablation techniques, the supporting evidence, and clinical application of IGA in the treatment of primary liver and kidney cancers.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 175-186 |
| Number of pages | 12 |
| Journal | Nature Reviews Clinical Oncology |
| Volume | 12 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 28 2015 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Medicine(all)
Cite this
Image-guided ablation of primary liver and renal tumours. / Breen, David J.; Lencioni, Riccardo.
In: Nature Reviews Clinical Oncology, Vol. 12, No. 3, 28.03.2015, p. 175-186.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Image-guided ablation of primary liver and renal tumours
AU - Breen, David J.
AU - Lencioni, Riccardo
PY - 2015/3/28
Y1 - 2015/3/28
N2 - Image-guided ablation (IGA) techniques have evolved considerably over the past 20 years and are increasingly used to definitively treat small primary cancers of the liver and kidney. IGA is recommended by most guidelines as the best therapeutic choice for patients with early stage hepatocellular carcinoma (HCC)-defined as either a single tumour smaller than 5 cm or up to three nodules smaller than 3 cm-when surgical options are precluded, and has potential as first-line therapy, in lieu of surgery, for patients with very early stage tumours smaller than 2 cm. With regard to renal cell carcinoma, despite the absence of any randomized trial comparing the outcomes of IGA with those of standard partial nephrectomy, a growing amount of data demonstrate robust oncological outcomes for this minimally invasive approach and testify to its potential as a standard-of-care treatment. Herein, we review the various ablation techniques, the supporting evidence, and clinical application of IGA in the treatment of primary liver and kidney cancers.
AB - Image-guided ablation (IGA) techniques have evolved considerably over the past 20 years and are increasingly used to definitively treat small primary cancers of the liver and kidney. IGA is recommended by most guidelines as the best therapeutic choice for patients with early stage hepatocellular carcinoma (HCC)-defined as either a single tumour smaller than 5 cm or up to three nodules smaller than 3 cm-when surgical options are precluded, and has potential as first-line therapy, in lieu of surgery, for patients with very early stage tumours smaller than 2 cm. With regard to renal cell carcinoma, despite the absence of any randomized trial comparing the outcomes of IGA with those of standard partial nephrectomy, a growing amount of data demonstrate robust oncological outcomes for this minimally invasive approach and testify to its potential as a standard-of-care treatment. Herein, we review the various ablation techniques, the supporting evidence, and clinical application of IGA in the treatment of primary liver and kidney cancers.
UR - http://www.scopus.com/inward/record.url?scp=84923817508&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923817508&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2014.237
DO - 10.1038/nrclinonc.2014.237
M3 - Article
C2 - 25601446
AN - SCOPUS:84923817508
VL - 12
SP - 175
EP - 186
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
SN - 1759-4774
IS - 3
ER -